Cidara Therapeutics (NASDAQ: CDTX) saw a 7% increase in its stock price after announcing the dosing of the first patients in a phase 3 trial for its investigational flu treatment, CD388. The treatment targets seasonal influenza in high-risk populations and has shown promising results in a phase 2b trial. The phase 3 trial will include both youth and adults, with at least 10% of participants being immunocompromised. CD388’s non-vaccine preventive nature could be advantageous in situations where vaccines are not effective or are perceived as harmful. With flu season approaching, the timing of this announcement is strategic, potentially leading to commercial success if approved by regulators.

Read more at Yahoo Finance: Why Cidara Therapeutics Was Such a Healthy Stock Today